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ABSTRACT
Background: The overexpression of an efflux protein, p-glycoprotein (P-gp), is a leading
cause of multi drug resistance (MDR). This research project is based on designing
emulsions containing optimal doses of cyclosporine (CyA) and Pluronic® P-85 (P85),
two agents found to be effective in inhibiting P-gp.
Study Objective: To investigate whether CyA exposure affects the quantity or
functionality of P-gp in vitro.
Methods: To study the functionality of P-gp, MDR cells were incubated with CyA
solutions containing the P-gp substrate and fluorescent dye Rhodamine 123 (RI23). P-gp
inhibition was measured by fluorescence spectrophotometry, which indicates the
accumulation of R123 inside the cells. This was repeated with the surfactant P85, a
component of emulsions, in solution with R123. Optimal doses were selected and used to
prepare O/W sub-micron emulsions loaded with CyA, R123, and P85. The accumulation
of R123 in the MDR cells when incubated with emulsions was then compared to the
accumulation seen with the CyA or P85 solutions. To study the quantity of P-gp as the
cell line ages, Western blotting was performed on aging cell passages.
Results: Out of the concentration range 1u.M - 25 uM for CyA and 100-1000 ug/ml, of
P85, 15 uM CyA and 200-500 ug/ml. P85 led to the greatest R123 uptake. The R123
accumulation with CyA solutions was fivefold greater than with CyA emulsions. Other
studies suggest that surfactants such as P85 encapsulate CyA or R123 by micelle
formation making them unavailable to interact with the cell. Western blotting showed
that the quantity of P-gp decreases as the cell line ages. However, earlier passages had
greater R 123 accumulation than later passages when exposed to CyA solutions which
remains unexplained.
Conclusions: Although both CyA and P85 led to greater P-gp inhibition at higher
concentrations, their combined effect in emulsions was not synergistic; this may be
explained by the micellization of the substrates by P85. The effect of aging on P-gp
functionality was inconclusive.
x
CHAPTER I
INTRODUCTION
1
1.1 BACKGROUND
Cancer is the second leading cause of death in the United States, exceeded only by
heart disease, 1 and is the leading cause of mortality in Americans younger than 85 years,2
accounting for nearly 1 of every 4 deaths.3 Due to the unpredictable nature of the disease,
cancer affects patients and their families, friends, and caregivers emotionally, physically,
socially, and spiritually as they often have to deal with the reality of poor prognosis and
in some cases, terminal illness. Patients and their families often express fear not only
towards the disease itself, but also towards the aggressive treatment and its cytotoxic
adverse effects on the human body. The financial costs of cancer are also overwhelming
for families and for the healthcare system as a whole. According to the National Institutes
of Health, cancer cost the United States an estimated $263.8 billion in medical costs and
lost productivity in 2010.1 The statistics on cancer survival rates and its increasing
incidence can also be very intimidating. The National Cancer Institute estimates that
nearly 12 million Americans with a history of cancer were alive in January 2008, about
1,638, 910 new cancer cases are expected to be diagnosed in 2012, and more than 577,
190 Americans are expected to die of cancer in 2012, which accounts for more than 1,500
people a day.' The increasing incidence of the disease is partly due to more efficient
screening tools that detect cancer earlier, leading to earlier initial therapy and better cure
rates. Accordingly, the number of survivors increased from 3 million in 1971 to 9.8
million in 2001 and 11.7 million in 2007.4 The five year survival rate for all cancers
diagnosed between 2001 and 2007 is 67% up from 47% in 1975-1977 _3
Despite better screening methods, newer treatments, and years of research on the
disease, the mechanisms by which cancer occurs are still incompletely understood.
Although cancer is characterized by uncontrolled cellular growth, local tissue invasion,
and distant metastases, it is actually a group of more than 100 different diseases that are
each strongly influenced by host characteristics and genetics? The four most common
cancers are prostate, breast, lung, and colorectal cancer' with lung cancer being the most
common cause of cancer related death (i.e., 160,700 deaths estimated for 2012). Five year
survival rates (i.e., the percentage of people who live at least five years post-diagnosis)
can range anywhere from 6% for all stages of pancreatic cancer to 99% for all stages of
prostate cancer.' The response to treatment is also highly variable and depends on the
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type of cancer, the size of the tumor at diagnosis, the presence of metastasis or co-morbid
conditions, and the pathway of genetic mutations that resulted in malignancy. For
example, regarding the former point, breast cancers that overexpress the HER-2
oncogene are most sensitive to anthracycline based regimens and tumors with EGFR
(epithelial growth factor receptor) mutations that resulted in enhanced tyrosine kinase
activity are more likely to respond to the tyrosine kinase inhibitor gefitinih.'
100,000 • Female deaths
300,000 -r----------------------
29%
29%
200,000
• Male new cases
150,000 • Male deaths
14% 14%
29% • Female new cases
50,000
a
Prostate Cancer Breast Cancer Lung Cancer Colon Cancer
Figure 1.1 Estimated numbers of new cases, estimated deaths, and percentage
occurrence of cancer for males and females for the top four leading cancers in the
year 2012. (adapted from Cancer Facts & Figures' provided by the American Cancer
Society)
There are several public health challenges regarding the prevention of cancer, the
biggest being effective screening tests for patients. Because cancers are most curable with
surgery or radiation before they have metastasized, early detection and treatment have
obvious potential benefits. In addition, small tumors are more responsive to
chemotherapy. Early diagnosis is difficult for many cancers because they do not produce
clinical signs or symptoms until they have become large or have metastasized. In fact, it
takes about 109 cancer cells for a tumor to be clinically detectable by palpation or
3
radiography and a tumor possessing 1012 cancer cells is considered lethal. Thus, a tumor
is clinically undetectable for most of its life span.' Other public health issues include
identifying any environmental carcinogens (i.e., tobacco, chemicals, radiation, and
certain viruses) that play a role in the development of cancer by producing genetic
damage that if not repaired results in irreversible cellular mutations. The biggest
challenge with identifying these environmental components is that ten or more years can
pass between exposure and detection of cancer.
Current evidence supports the concept of carcinogenesis as a multistage process that
IS genetically regulated and is caused by both the external environmental factors
mentioned above and internal cellular mechanisms, such as inherited mutations,
hormones and immune conditions.v' Once the normal mechanisms for control of growth
and proliferation are altered, the mutated cell has an altered response to its environment
and a selective growth advantage, giving it the potential to develop into a clonal
population of neoplastic cells. It may take up to twenty years for this population to
become clinically detectable. This period of time involves further genetic changes,
increased cell proliferation, invasion into local tissues and the development of
metastases.f In fact, many physicians have the opinion that many tumors have already
metastasized upon initial diagnosis, even if the metastasis are not yet detectable.
The era of modern cancer chemotherapy was born in World War I, when physicians
observed that nitrogen mustard gas caused a dramatic drop in the white blood cell count
of soldiers. Subsequently in 1941, Goodman and Gilman found that nitrogen mustard gas
is beneficial when administered to patients with lymphoma. Derivatives of nitrogen
mustard are still used today in chemotherapy regimens. Numerous antineoplastic agents
have been developed since then, and a variety of chemotherapy regimens have been
investigated in every type of cancer. Treatment with cytotoxic drugs is the primary
curative modality for a few diseases, including leukemias, lymphomas,
choriocarcinomas, and testicular cancer. Most solid tumors, however, are not curable
with chemotherapy alone, either because of the biology of the tumor or because of
advanced disease at presentation. Chemotherapy in this setting is often initiated for
palliative purposes to decrease tumor size or to retard growth enough to reduce untoward
symptoms caused by the tumor.'
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There are multiple reasons that chemotherapy fails or that cancers relapse. Because
most anticancer drugs have greater effect on rapidly dividing cells, tumors are most
sensitive to the effects of chemotherapy when the tumor is small and the growth fraction
is high. However, as the tumor size increases, it outgrows its blood and nutrient supply,
doubling time slows, and thus chemotherapy is less effective. Tumor burden also impacts
response to chemotherapy. The cell kill hypothesis states that a certain percentage of
cancer cells will be killed with each course of chemotherapy. For example, if a tumor
consists of 1000 cancer cells and the chemotherapy regimen kills 90% of the cells, then
10% or 100 cancer cells remain. The second chemotherapy course kills another 90% of
cells, and again only 10% or 10 cells remain. According to this hypothesis, the tumor
burden will never reach zero. Tumors consisting of less than 104 cells are believed to be
small enough for elimination by host factors, including immunological mechanisms, but
these factors must be in place for a cure to be possible. The limitations of this theory is
that it assumes that all cancers are equally responsive to chemotherapy and that
metastases do not occur?
Another major reason for the failure of chemotherapy is the occurrence of multidrug
resistance, where cancer cells have developed mechanisms to survive the cytotoxic
mechanisms of chemotherapeutic agents.' Because of the presence of a heterogenous
population of cells in a tumor, drug resistance is inevitable and combination
chemotherapy is given to target as many types of cells in the tumor as possible. Selection
of agents for combination chemotherapy regimens involves consideration of drug-
specific factors such as mechanism of action, antitumor activity, and toxicity profile.
With the availability of new targeted therapies, one area of research is to determine the
optimal ways to combine these agents, both with traditional chemotherapy agents and
other targeted agents. In theory, these agents make ideal combinations because they target
the underlying cancer biology while avoiding typical chemotherapy adverse effects.
Despite the number of new agents, it has been found that many cancers are intrinsically
resistant to initial chemotherapeutic regimens and can also acquire resistance after
exposure to chemotherapy. This chapter addresses some of the causes of multiple drug
resistance (MDR), with a focus on the overexpression of P-glycoprotein (P-gp), and the
development and effectiveness of compounds that are MDR modulators.
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1.2 MULTIFACTORIAL MULTIDRUG RESISTANCE
In current clinical practice, resistance is mostly considered to be caused by alterations
in drug targets and is overcome by using multiple chemotherapeutic agents with different
mechanisms of action. Taking the definition a step further, multi drug resistance is the
phenomenon in which cancer cells when exposed to a single drug become resistant to an
array of anticancer drugs with different chemical structures and molecular mechanisms of
action. In a review by Lin and Yamazaki, it was stated that the ability of cancer cells to
become simultaneously resistant to different anticancer drugs is the primary reason for
the high failure rate of cancer chemotherapy." A better term to describe the failure of
chemotherapy would be multifactorial multidrug resistance, which is the phenomenon
when different cells in a heterogeneous cell population acquire different mechanisms of
resistance.' Because of the multifactorial nature, it is very difficult to accurately assess
the specific mechanisms and their relative contribution to drug resistance for different
types of tumors.l' It is thought that some cells within a tumor may be inherently resistant
to cell killing whereas other acquire resistance after exposure to chemotherapy through
genetic alterations that convey selective survival advantages' More research on what
types of tumors display what type of resistance and at what time point in their
development could greatly improve the use of chemotherapy in clinical practice.
Reduced accumulation of drugs within cells as the cause of MDR was the conclusion
by early physiologic and pharmacologic studies of MDR mutant cell lines. This reduced
accumulation was either due to increased drug efflux or changes in cell permeability and
could be demonstrated for most cell lines and for most drugs analyzed." Further research
found that often different mechanisms are switched on in cells, and that one mechanism
might influence the activation of a different mechanism. The most investigated
mechanisms of multi drug resistance are described in Table 1.1.
The mechanisms of MDR are interconnected in ways not completely understood
by researchers. For example, recent studies revealed that the induction of the CYP450
enzyme system coordinates with the overexpression of P-gp, leading to both reduced
plasma levels of chemotherapy and decreased intracellular concentrations of the drug. II
Other studies have shown that inhibition of the pro-apoptotic gene, p53, results in the
overexpression of P-gp, leading to increased antiapoptosis and increased drug efflux.lo
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The development of drugs to target these mechanisms of resistance or prevent their
occurrence would greatly improve treatment efficacy. However, due to the multifactorial
nature of drug resistance both intracellularly and intercellularly, this seems nearly
impossible to overcome unless a modulating agent that can reverse multiple cellular
targets or a final common target known to confer drug resistance becomes available. The
next section discusses the best characterized mechanism of multi drug resistance
pharmacologically, biochemically, and genetically as well as the development of drugs to
inhibit it.
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Table 1.1 Mechanisms of Multidrug Resistance
Mechanism Examples
Increased
. . 10antiapoptosis
Alterations in
drug target?' I 0
• Reduced levels of topoisomerase II, a target of doxorubicin.
• Increased quantities of dihydrofolate reductase, a target of
methotrexate.
• Mutations in the ~-tubulins, a target of paclitaxel.
Reduced drug
IIuptake
• Water soluble drugs that piggyback on transporters rely on the
presence of sufficient blood flow to the tumor.
• Endocytosis might be impaired preventing the accumulation of
drugs that enter by means of endocytosis.
• Drugs that piggy back on transporters or rely on endocytosis
include methotrexate, 5-fluorouracil, 8-azaguanine, and cisplatin.
Drug efflux
out of cells8,10
• Alterations 111 phospholipid membrane compositions expel
anticancer drugs through increased cell permeability.
• Electron microscopy studies show increased permeability in drug
resistant cells, as compared to drug sensitive cells.
• Decreased drug accumulation has been associated with the
overexpression of efflux proteins, such as P-gp.
drug
Intracell ular
. 7sequestratlOn
Detoxification
of the drug in
the cells
• Several studies show ATP dependent sequestration of the drugs
inside cytoplasmic vesicles followed by extrusion of the drug.
• Weak basic drugs are protonated, and thus inactivated, 111
intracellular environments with an abnormally elevated pH.
A major protein responsible for generating pH gradients across•
organelle membranes is a vacuolar H-ATPase. Inhibitors of this
protein abolish drug sequestration in vesicles and reverse MDR.
• Drug resistant cell lines express increased levels of glutathione-
S-transferase, an intracellular enzyme that conjugates with drugs
to increase drug solubility for cell export.
• Cells acquire changes in apoptotic pathways.
• Cells activate mechanisms of DNA repair
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1.3 FUNCTION OF P-GLYCOPROTEIN IN MULTIDRUG RESISTANCE
P-glycoprotein is a member of the ATP-binding cassette (ABC) superfamily. This
group of proteins has received considerable attention because of the protective role they
play in numerous tissues by effluxing toxins out of cells. They are also associated with
other clinical challenges such as cystic fibrosis and antibiotic resistance. 12 Although the
overexpression of other proteins belonging to this family, such as the multidrug
resistance protein (MRP), lung related protein (LRP), and breast cancer resistance protein
(BCRP) may also contribute to the multidrug resistance profile, this section will focus
exclusively on the role of P-gp. Although P-gp has been extensively studied, the
mechanisms through which P-gp mediates the pleiotropic MDR phenotype are still
incompletely understood. Multiple models for its function have been proposed and are
reviewed in the following sub-sections.
A. The discovery of P-glycoprotein
P-gp was purified in 1979, and strong evidence in support of its role in pleiotropic
drug resistance came in 1982, when it was shown that DNA from resistant cell lines
transferred to nonresistant cells was able to confer resistance that correlated with the
expression of a 170kD protein, later termed P-gp by Ling and colleagues. The gene for P-
gp, called MDR1, was cloned in 1985 and the protein's putative function as an energy
I d 13dependent pump that expels small molecules from inside cells was postu ate .
Furthermore, attempts to isolate amplified genes in MDR cells have invariably led those
belonging to P-gp; thus, overexpression of a single P-gp gene is the predominant genetic
alteration in MDR and is sufficient to confer the MDR phenotype." P-gp was discovered
to be located in cell membranes when fluorescently labeled drugs such as vinblastine
were bound by the membranes of drug resistant cells better than by the membranes of
sensitive cells.1o The expression of P-gp was then also shown to correlate with multi drug
resistance in mouse, hamster, human, and other cells, both in vitro and in vivo.5
B. Expression and function of P-glycoprotein in different tissues
P-gp is expressed not only in tumor cells but also in normal tissues such as the
liver, kidneys, small and large intestines, brains, testis, muscle tissue, placenta and
adrenals. In the intestine, P-gp is located in the apical domain of enterocytes where it
limits the uptake and absorption of drugs and other substrates from the intestine into the
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systemic circulation. The presence of P-gp in the capillary endothelial cells of the brain
and testis also limits the uptake of substrates into these tissues. In the luminal membrane
of renal proximal tubules and in the canalicular domain of hepatocytes, P-gp plays a role
in the urinary and biliary excretion of xenobiotics and endogenous compounds. Various
types of structurally unrelated drugs have been found to be substrates for P-gp. Therefore,
it is recognized as an important regulator for the pharmacokinetics of drugs. In addition,
it has been demonstrated that P-gp is a key protein for drug-drug interactions.
Documented drug interactions with P-gp occur between digoxin and calcium antagonists,
antihypertensives, antiarrhythmic agents, anti anginal drugs and simvastatin.i '
There is no evidence that normal tissue P-gp differs in structure, function,
substrate specificity or affinity from the P-gp found in human tumors. Mice deficient in
P-gp appear completely healthy, yet are exceptionally sensitive to certain exogenous P-gp
substrates. For example, they are 100-fold more sensitive to the oral administration of the
pesticide ivermectin; levels of this neurotoxic drug in the central nervous system (CNS)
were 100 fold higher than in normal mice. These same mice were three to forty fold more
sensitive to the intravenous infusion of vinblastine. Therefore, the likelihood of being
able to modulate tumor P-gp without having some efIect on normal tissue P-gp seems
unlikely. Possible pharmacological consequences of normal tissue P-gp inhibition would
then include (1) increased toxicity of anticancer drugs including unveiling of new CNS
toxicities which are normally protected by P-gp; and (2) increased myelosuppression by
increased sensitivity of hematopoietic stem cells which express p_gp.15
Data from clinical trials has been used in an attempt to establish a clear
relationship between P-gp expression and overall prognosis or response to chemotherapy.
Two studies demonstrated that P-gp expression was highest in tumors from colon,
adrenal, pancreatic, mammary, and renal tissue, even in the absence of any prior
chemotherapy. Tumors emanating from tissues with a normally high expression of P-gp
displayed an inherent resistance to many chemotherapy regimes. However, due to the
poor design of clinical trials, it has been difficult to determine the relationship between
initial P-gp expression and prognosis implications. Some confounding factors include
low patient sample numbers and variability in prior treatment regimens and disease status
among the patient population. The detection methods for P-gp expression were also
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hampered by problems such as (1) variations 111 preparation and fixation of tissue
samples; (2) contamination with normal tissue expression of P-gp; and (3) low and
heterogeneous expression patterns difficult to detect by current methods. Nevertheless,
negative prognostic implications of P-gp expression have been best established in many
types of leukemias, neuroblastomas, breast cancer, and several sarcomas. Treatment
regimens against cancers with a defined involvement ofP-gp in mediating drug resistance
would benefit significantly from the development of selective P-gp inhibitors. Indeed, the
last twenty years have seen a significant effort designed to restore chemotherapy
sensitivity through inhibition ofP-gp function.l"
C. Drug transport by P-glycoprotein is coupled to ATP-hydrolysis
During the first discoveries of P-gp, it was found that enhanced activity of an
energy dependent efflux pump led to the reduced accumulation of anthracyclines in tissue
culture. When inhibitors of oxidative phosphorylation were added to a glucose deficient
medium, the concentration of drug in resistant cells began to equal that of sensitive cells;
when glucose was introduced to the medium, resistant cells began to efflux the drug at a
much greater rate than the sensitive cells showing that efflux mechanism required
energy.' Furthermore, Cohen and collaborators have shown consistent differences in
energy metabolism between resistant and sensitive cells. Although MDR cells tend to
have a higher energy requirement in general, there was a much higher metabolism of
ATP when the gene for P-gp was transfected into cell lines.8
Further studies have confirmed that Pvgp drug transport IS coupled to ATP
hydrolysis. P-gp is an unusual ATPase because it exhibits a high level of constitutive
ATPase activity in the apparent absence of substrates and that the rate of drug transport
appears to be many folds lower than the rate of ATP hydrolysis. Sharom et al estimated
that an additional four molecules of ATP were hydrolyzed for each molecule of
colchicine, a P-gp substrate, transported; this was a 15% increase in ATP hydrolysis
measured against a background of constitutive ATPase activity.l'' It is reasonable to
believe that multiple molecules of ATP are hydrolyzed during the transport of substrates,
some hydrolytic events for transport and others to reset the transporter to its original
state.18 Another puzzling observation is that not all substrates stimulate activity; several
transported substrates actually inhibit activity in a concentration-dependent manner. It
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has been suggested that overlapping stimulatory and inhibitory drug binding sites exist
within P-gp. In addition, conflicting results have been obtained in different systems; the
transport substrate vinblastine inhibited ATPase activity of P-gp in Chinese hamster
ovary cells, whereas it simulated the activity of P-gp in other types of cells. It also
appears that drug modulators of P-gp ATPase can be greatly affected by the local lipid
environment and the presence of detergents.l"
D. Models for P-glycoprotein function
Working models for the structure and function of P-gp have been formulated from
the results of sequence analysis, but the exact efflux mechanism of the protein is not
completely understood. Several models have been proposed and are explained below.
1. Classic Pump Model- Also known as the "vacuum cleaner model," this
hypothesis proposes that drugs and chemosensitizers interact with different overlapping
regions of a single flexible drug binding site that is large enough to accommodate more
than one compound, explaining the broad specificity of Pgp.12 The majority of
experimental data strongly supports the classic pump model because of evidence for a
direct interaction of chemosensitizers with P-gp through (1) drug binding studies; (2)
photoaffinity labeling experiments; (3) the demonstration of drug stimulated ATPase
activity in direct proportion to P-gp transport activity; and (4) a variety of amino acid
substitutions that alter P-gp transport specificity."
The classic pump model suggests that drugs must intercalate into the lipid bilayer
in order to be recognized by the transporter, which pumps it out of the bilayer. This is
supported by evidence that P-gp can be labeled with hydrophobic agents such as
forskolin and its derivates; the more lipophilic the derivative the more efficiently it labels
P-gp. Since MDR drugs compete with forskolin for labeling, this implies that the
substrate binding site is accessible from the lipid phase.l ' Furthermore, P-gp expressing
cells can efflux the hydrophobic acetoxymethyl (AM) derivatives of several fluorescent
indicator dyes. If the nonfluorescent AM derivative gains access to the cytosol, it is
rapidly hydrolyzed by cytosolic esterases to the highly t1uorescent free acid form, which
is trapped in the cytosol since it is not a P-gp substrate. However, in MDR cells, the free
acid forms do not accumulate, implying that the AM compounds are expelled from the
membrane by P-gp before they reach the cytosol."
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Other evidence shows that there may be more than one route for substrates to gain
access to P-gp. For example, colchicine is transported very well by P-gp, despite being a
relatively hydrophilic compound. Colchicine is unable to compete with other more
hydrophobic drugs in photoaffinity labeling experiments, suggesting that drugs with a
high degree of polarity may gain access to the transporter from the cytosol, where more
hydrophobic compounds may interact with the protein from within the bilayer. Therefore,
the degree of lipophilicity suggests (1) the location that the compound will interact with
P-gp; and (2) P-gp may have multiple drug binding sites. We would also expect P-gp to
be sensitive to changes in its lipid environment, since these would affect substrate
presentation as well as protein function. Furthermore, the actual drug concentration seen
by the transporter in the lipid bilayer would be different than the aqueous concentration
and would depend on the partition coefficient of the drug between the aqueous phase and
the lipid bilayer. Well-defined binding curves can be obtained for interaction of a variety
of different substrates with P-gp. The transport rates for P-gp substrates (i.e., Kd values)
cover a 1000 fold range; this suggests that the protein does, in fact, effectively
discriminate between different compounds, resulting in a specific, measurable binding
affinity. It also suggests that P-gp may have more than one binding site.17
2. Flippase model - P-gp may have evolved to protect membranes from agents
which intercalate and introduce discontinuities in the bilayer which may be deleterious to
membrane function. P-gp, therefore, may function to clean out the membrane. This model
proposes that P-gp does not have specific binding sites, but translocates specific lipids
from one leaflet of the bilayer to the other in order to maintain lipid symmetry within the
membrane; intercalated drugs are flipped along with these lipids by mistake. This model
speculates that ATP is constantly being hydrolyzed to produce a moving staircase, or
waterwheel, in which any drug that happens to fall into the transport chamber will be
extruded.l ' It may have a higher rate of ATPase activity in cancerous cells because of the
presence of more abnormalities in the membranes of cancerous cells as opposed to non-
cancerous cells.
This model makes the important assumption that substrates partition into the lipid
phase prior to interacting with P-gp itself. P-gp can then either pump the drug from the
inner leaflet to the outer leaflet of the lipid bilayer or to the extracellular medium.
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Different substrates will be transported at different rates depending on their relative lipid
solubility. According to this model, those observations that specific mutations in P-gp
change substrate specificity is not due to a change in drug binding site, but rather to P-gp
interacting with the membrane differently.
If P-gp does not interact with substrates directly, then how can it discriminate
between substrates, such as chemotherapeutic drugs and inhibitors of P-gp that sensitize
the cell to chemotherapy? Eytan et al proposes that both drugs and chemosensitizers are
handled by P-gp in exactly the same way; they are transported with hydrolysis of ATP.17
Compounds that have been flipped to the outer leaflet by P-gp can flop back into the
inner leaflet before interacting with P-gp once more and being flipped again. The true
difference between P-gp substrates and inhibitors would depend on the rate at which
drugs flip flop across the membrane. For substrates, the rate of transmembrane movement
is presumably slow enough that flipping by P-gp can keep pace and a drug gradient is
established. For chemosensitizers, the rate of transmembrane movement is so rapid that
flipping via P-gp cannot keep pace with it17. Agents such as detergents that modify the
membrane permeability would also modify the ability of P-gp to come in contact with
chemotherapeutic agents. In other words, in rigid lipid vesicles where transmembrane
drug movement is slow, P-gp would be able to come in contact with chemotherapeutic
agents. In highly fluid lipid vesicles, however, chemotherapeutic agents may be able to
diffuse into the cytosol more quickly, avoiding contact with P-gp. One other possible
alternative explanation for the mode of action of some chemosensitizers in interfering
with the action of P-gp may be that they are ATPase inhibitors. For example, the
flavonoid quercetin has been proposed to block Pvgp function in intact cells and
reconstituted membrane systems by inhibiting the ATPase activity of P-gp, which is
required for drug transport. 17
3. Altered partitioning model- This model proposes that P-gp modifies the pH or
the membrane potential across the plasma membrane of MDR cells. These perturbations
are believed to have multiple effects on the diffusion and retention of chemotherapeutic
drugs, which result in decreased drug accumulation inside MDR cells as well as the pH
dependent binding of drug molecules to their targets.i" In support of this proposal,
increased intracellular pH and altered membrane potential, relative to the drug sensitive
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parent, have been observed in several series of MDR cell lines.17 The major appeal of this
hypothesis is its explanation of the unusual ability of P-gp to act on a vast number of
structurally unrelated substrates. The evidence for the altered partitioning model of P-gp
function is not as strong as it is for the other two, however. For example, alterations in pH
or membrane potential are not found in all MDR expressing cells and these changes are
not of sufficient magnitude to account for the up to several hundred fold increases in drug
resistance of some MDR cells. It is likely that these changes in biophysical properties of
the cell might well be epiphenomena associated with the prolonged selection of cells in
cytotoxic drugs or they might be secondary to the action of P-gp itself, which transports
many positively charged as well as neutral hydrophobic substrates.Y In other words, this
theory does not explain how changes in electrochemical properties of the membrane
results in decreased retention of neutral molecules such as colchicine.
In conclusion, each of these alternative models for the mechanisms of P-gp are
attractive, but are difficult to reconcile with the conflicting evidence that has been
published regarding this topic. The issue of whether P-gp directly interacts with
compounds, indirectly interacts with compounds, or modifies the intracellular
environment of cells will continue to be an unresolved issue generating controversy in the
field.21 Most likely, all three of these models contribute somewhat to the function of P-gp.
1.4 MODULATORS OF P-GLYCOPROTEIN FUNCTION
In 1988, a diverse group of compounds was found to reverse the reduction in drug
accumulation in multidrug resistant cells and thus circumvent multidrug resistance. Since
then, there has been the idea that modifying agents with little or no cytotoxic effects may
be useful for administration in conjunction with cytotoxic drugs to overcome multi drug
resistance in clinical chcmotherapy' The concept of reversing MDR with antagonists of
P-gp function, termed chemosensitizers, became more of a reality when Tsuruo and co-
workers noted that the calcium channel blocker verapamil blocked vincristine resistance, ,
in vitro and in vivo using a murine leukemia model.i'' A typical compound in the MDR
spectrum is large (molecular weight>400), hydrophobic, amphipathic, with a planar ring
system, and often carries a positive charge at physiological pH. However, not all putative
P-gp substrates fall into this category; many are uncharged at physiological pH
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(colchicine) and several uncharged cyclic and linear hydrophobic peptides and
ionophores have been described as P-gp substrates. 17
The mechanism for the inhibition of P-gp function differs with various classes of
compounds. The three main mechanisms are (1) direct interaction with drug-biding sites,
thus blocking transport by acting as a competitive or non-competitive inhibitor; (2)
inhibition of ATP hydrolysis or the coupling of ATP to P-gp; and (3) interaction with the
lipid membrane of the cell thus modifying the interaction of P-gp with the cell
membrane. Though reversal of MDR is a common Ending, the degree to which these
agents achieve this varies. Almost complete reversal of the MDR phenotype has been
reported in a number of cases but only partial reversal in others. Furthermore,
measurements of drug accumulation in these experiments show that complete reversal of
the MDR phenotype is not always accompanied by an increased accumulation of drug to
levels observed in the drug-sensitive parental cell lines.22 The success with which agents
can reverse MDR may depend on the agent used and the degree of drug resistance to be
overcome. Table 1.2 gives a better idea of the smorgasbord of chemosensitizers and the
degree of resistance they can overcome in different cell lines.
16
Table 1.2
Chemosensitizers
Calcium channel blockers
(i.e. diltiazem, nicardipine,
nilodipine, minodipine)
Verapamil
Calcium antagonists and
calmodulin inhibitors
(i.e., cyclosporine)
Phenothiazine and
naphthalene-sulfonamide
calmodulin inhibitors
Use of common drugs to modify multidrug resistance='
Evidence
• Completely circumvented the MDR phenotype in a
vincristine selected cell line.
• Only reversed adriamycin resistance 111 an
adriamycin selected cell line 10-30 fold.
• Reversed adriamycin resistance three to four fold in
human ovarian cancer cells.
• Reported to circumvent vincristine resistance in
human K562/VCR cells, yet affects adriamycin
cytotoxicity only marginally.
• Dramatic decrease in resistance for vinca alkaloids
but only slight decrease in resistance to certain
anthracyclines,
colchicine.
epipodophyllotoxins, and
• Reported not to chemosensitize drug-sensitive cells
in a number of studies.
• Other studies report sensitization 111 some drug-
resistant cells, but the effect IS much less
pronounced than that observed in other MDR cells.
• Only found to chemosensitize MDR cells if
exposed to them in the long term.
The reversal of MDR through direct interaction with P-gp has clearly been widely
investigated, and the development of MDR modulators has been carried out with sights
set on the reversal of MDR. Consequently, a variety of compounds have been discovered
to have activity to reverse P-gp mediated MDR and some MDR modulators have
undergone clinical trials. Table 1.3 describes the different classes of MDR modulators.
One of the most important lessons learned from Phase I and II trials is that the
first generation chemosensitizers are not ideal for reversing MDR in the clinic. This is
because it is difficult to obtain adequate concentrations of the chemosensitizer in patients
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1--
without toxicity. The ideal chemosensitizer would have (1) high level of ffic .
e icacy with
complete inhibition of P-gp function at low concentration; (2) no ph: . ..
almacoktnetlC
interactions that cause increased exposure to cytotoxic drugs; and (3) selectiv . 1 ib..
e In 11 rtion
of P-gp function in tumors while sparing P-gp function in normal tissues_2o
The second generation as well as first generation MDR modulators I· fl
n uence the
pharmacokinetics of anticancer drugs through the inhibition of P-gp mediated biliary
excretion or competition for enzyme-mediated hepatic or intestinal metabolisn1 1'1 1
. 1US,t 1e
second generation MDR modulators had unacceptable toxicity due to increased levels of
cytotoxic chemotherapeutic agents. This necessitated reductions in the dose of a ti
n icancer
drugs in clinical trials. For example, in a phase I clinical study, intravenous infusion of
PSC833 resulted in an 89% increase in the area under the curve (AUC) of etoposide, with
a clearance that decreased by 46%. In this study, a 25% dose reduction of etoposide was
required due to exacerbated hematological toxicity (i.e., neutropenia). Similarly, in
another clinical study, oral administration of PSC833 caused a twofold increase in the
etoposide AUC in patients. Again, a 50-60% dose reduction of etoposide was required
because of myelosuppression. From a clinical point of view, it is very attractive to reverse
MDR by inhibiting the eft1ux transport activity of P-gp. However, as noted above, the
clinical and toxicological outcomes clinically are disappointing. One of the main reasons
is that the addition of P-gp inhibitors fails to improve the toxicity profiles of anticancer
drugs. Although P-gp modulators might effectively inhibit P-gp mediated MDR in tumor
cells and restore drug sensitivity, the modulators could also inhibit the P-gp protective
function in normal tissues, particularly for bone marrow and intestinal epithelium."
The inactivation of gene expression at the mRNA levels as a means to reduce the
amount of protein expressed has long been realized to be a potentially powerful
therapeutic strategy. To date, procedures to selectively block the expression of Pvgp
mRNA include the use of antisense oligonucleotides or hammerhead ribozymes. Some
reports have demonstrated that antisense oligonucleotides modulate P-gp dependent
MDR in cultured cells. However, the clinical benefit of reversing MDR using antisense
oligonucleotides has not been realized to date. An anti-P-gp monoclonal antibody, MRK-
16 has also been developed. Preclinical studies showed that MRK -16 and cyclosporine, a,
first generation P-gp inhibitor, are synergistic in their inhibition of P-gp. This suggests
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1st Generation 211(1 generation 3rt' generation -
Defined as the drugs Analogs of the first generation Developed to overcome ---
currently in clinical demonstrated to be more some of the
use for other effective for the reversal of P- pharmacokinetic
purposes besides gp mediated MDR in vitro and interactions and increase
MDR. in animal studies. potency.
Verapamil Cinchonine OF 120918 (elacridar)
Cyclosporine Dexniguldipine LY33S979 (zosuquidar)
Amiodarone Dexverapamil R101933 (laniquidar)
Bepridil MS-209 XR-9S76 (tariquidar)
Dipyridamole PSC833 (valspodar) S9788
Nifedipine Toremifene
Progesterone VX-170 (biricodar)
Quinidine
Quinine
Tamoxifen
Trif1uoperazine
that separate but functionally complementary sites could be targeted to inhibit the eft1ux
pump.15 The next section will discuss a MDR modulator with a unique mechanisn) of
action against P-gp which could potentially be used in conjunction with another agent.
Table 1.3 First, Second, and Third generation multidrug resistant modulators14
1.5 LIPIDS AS MULTIDRUG RESISTANCE MODULATORS
A second class of chemosensitizers exists, consisting of agents such as detergents,
amphiphiles and membrane fluidizers. The enhanced cytotoxicity observed with these
agents in drug resistant cancer cells appears to be related to the affects of the detergent on
the P-gp drug eft1ux transport system. Nonionic surfactants such as Pluronic'[',
Cremophor EL®, Solutol HS IS@,Triton XIOO@,or polyoxyethylated derivatives of fatty
acids all exhibit an ability to enhance the cytotoxicity of antineoplastic agents in MDR
cells.7 The use of poly(ethylene oxide)-poly(propylene oxide) block copolymers
(Pluronic'") have been extensively studied as MDR modulators and will be the focus of
this section. It has been observed that the intracellular accumulation of doxorubicin in
resistant cancer cells expressing P-gp can be greatly enhanced by treatment with
Pluronic@.7 This conclusion has been reinforced by recent studies by Evers et al and
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Batrakova et al demonstrating that Pluronic® block copolymers profoundly increase
accumulation and permeability of various P-gp dependent drugs in cells which
overexpress Pvgp. There is increasing evidence suggesting that they also might have other
effects outside modifying the permeability of the cell membrane. For example, P-gp may
have inhibitory effects on other efflux proteins, may increase drug sequestration within
cytoplasmic vesicles, and may increase the metabolic activity of the glutathione S-
transferase intracellular enzymes.I
The reasons for a remarkable selectivity of Pluronic® block copolymers with
respect to MDR cells are not completely understood. One hypothesis is that the high rates
of energy consumption by drug efflux pumps, combined with Pluronic® induced
inhibition of respiration, determine the responsiveness of the resistant cells to the block
copolymer. It is also thought that the mitochondria may be a potential site of action for
Plutonic" block copolymers. It has long been known that nonionic polymeric detergents,
such as Tween 80® and Pluronic® can decrease oxidative metabolism of tissues. Rapoport
et al has shown that two Pluronic'" copolymers, Pluronic® P-85 and Pluronic® P-I05
reduce the activity of the electron transport chain in mitochondria. Under conditions in
which the respiration necessary for ATP synthesis is inhibited, the high rates of ATPase
activity by drug efflux pumps could result in a rapid exhaustion of intracellular ATP in
resistant cells. Alternatively, cells which do not exhibit these resistance mechanisms
would appear to be less responsive to inhibition of respiration and would not exhibit
energy depletion, at least to the extent observed in the resistant cells. Such a hypothesis is
in line with the earlier observation that resistant cells have an increased glucose
utilization rate compared to sensitive cells. Nevertheless, transient energy depletion, as a
result of exposure of the cells to Pluronic® in the absence of the chemotherapeutic agents,
does not induce a cytotoxic effect in either MDR or sensitive cells. However, if the
chemotherapeutic agent doxorubicin is present, then the exposure of MDR cells to the
combination of both drug and block copolymer results in a pronounced potentiation of
cytotoxic activity.i
It is likely that Pluronic® block copolymers have a double punch effect in MDR
cells through ATP depletion and membrane fluidization, which both have a combined
result of potent inhibition of P-gp. The most compelling evidence to support the idea that
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energy depletion contributes to the sensitization of MDR cells by Pluronic'" was obtained
in experiments using an energy supplementation system. These studies were based on the
observation that treatment of cells with dodecylamine in combination with Pluronic'" P-85
CP85) allows transport of ATP into the cells from the extracellular media. The use of this
system with MDR cells allowed restoration of intracellular ATP levels, which abolished
inhibition of the P-gp efflux system by P85 and substantially reduced the cytotoxic effect
of doxorubicin formulated with P85 in these cells. Since the block copolymer in this
experiment was still present and bound with the cell membranes, this ATP
supplementation study indicates that membrane fluidization alone may not be sufficient
for inhibition of the P-gp efflux system in MDR cells. On the other hand, energy
depletion alone in the absence of interaction of the block copolymer with the P-gp
containing membranes might also be insufficient to inhibit the eff1ux system. Therefore,
both membrane fluidization and energy depletion are critical for inhibition of the effect of
P85 on the P-gp efflux system in MDR cells.'
There are also different structure activity relationships between the different
copolymers of Pluronic@. For example, one study examined the effect of twenty block
copolymers having different lengths of hydrophilic and hydrophobic segments in MDR
cancer cell lines. These block copolymers were divided into three groups depending on
their number of hydrophobic segments; the first group had few hydrophobic segments,
the second had an intermediate amount of hydrophobic segments, and the third had a high
amount of hydrophobic segments. It was found that the first group of copolymers did not
transport well into cells, the third group accumulated within the lipid membrane but did
not transport into the cytosol, and the second group effectively transported into the cell.
According, only the copolymers of group two effectively depleted ATP levels. Among
this group, the Pluronic@ copolymer with 85 segments, P85, had the most potent MDR
modulation and is the Pluronic@ copolymer studied in this work.?
There are also dose dependent effects of Pluronic@ on MDR cells. Pluronic block
copolymers have the ability to self-assemble into micelles, which are basically an
aggregate of the copolymers into a spherical form. The critical micelle concentration
CCMC) is the concentration at which the individual copolymer units, termed unimers, self
assemble into micelles through a process called micellization. The driving force for
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micellization is the interaction of the hydrophobic segments. Therefore, Pluronic® block
COpolymers with a greater number of hydrophobic segments will have a lower critical
micelle concentration. Once copolymers aggregate into micelles, they are no longer able
to interact with MDR cells; only unimers are able to modulate MDR. Therefore, the
critical micelle concentration determines the maximal achievable concentration of
Pluronic® unimers to which MDR cells will be exposed, thereby defining the biological
effects which Pluronic® itself will exert on these cells. Studies by Batrakova et al. have
demonstrated that both inhibition of the P-gp efflux system by Pluronic® and the
potentiation of doxorubicin activity by Pluronic® in MDR cancer cells occur at block
COpolymer concentrations below the critical micelle concentration. As a result, the
accumulation and cytotoxicity of drugs in MDR cells increase with increasing
concentrations of Pluronic® until the critical micelle concentration is reached."
The effects of using Pluronic® block copolymers as MDR modulators may
significantly improve the response to chemotherapy. They may have a synergistic effect
when formulated with other chemosensitizers, but this has not been extensively
Investigated to date. Table 1.4 nicely reviews some of the publications regarding the use
of deterg , . .' IIents 111 multi drug resistant cancer ce s.
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1.6 SIGNIFICANCE OF P-GLYCOPROTEIN IN CLINICAL TRIALS
The burden of proof in establishing whether P-gp expression is therapeutically
relevant requires that clinical correlations be made to determine its prognostic
importance. If P-gp is determined to be a prognostic factor for poor therapeutic outcomes,
then the ultimate goal is to circumvent or eliminate this form of clinical drug resistance.
Although overexpression of P-gp has unequivocally been demonstrated to cause drug
resistance to natural product agents in vitro, the relevance of P-gp to drug resistance in
vivo is more controversial. In part, this controversy stems from divergent results which
have been reported for the detection of P-gp in certain rnalignancies.r'' In a meta analysis
of a total of 8,323 tumors were evaluated for P-gp expression. Expression of P-gp varied
considerably among these tumors, from 0% for prostate carcinomas to 88% for
endometrial cancers, with a mean frequency of 40%. This meant that 60% of the tumor
samples examined did not express P-gp. Subsequent to treatment with anticancer drugs,
an increase was observed in the frequency of P-gp expression in some tumors. For
example, treated tumors expressed P-gp 4% and 51% more frequently for sarcomas and
lung carcinomas, respectively. The correlation between clinical responses to
chemotherapy and P-gp expression was also analyzed for 1,059 tumors. Approximately
70% of the tumors without P-gp expression responded to drug therapy, whereas 45% of
tumors with P-gp expression responded to chemotherapy. However, it is important to
emphasize that although the response rate was higher for the P-gp negative tumors than
for P-gp positive tumors, almost half of the P-gp positive tumors responded to
chemotherapy. These results indicate that although P-gp plays a role in drug resistance, it
is not the only mechanism responsible for drug resistance. Therefore, it is evident that
efforts to convert drug resistance into drug sensitivity by modulating P-gp functional
activity can only partially improve chemotherapy."
Numerous methods to detect P-gp in clinical specimens have been published.
These methods may be categorized on the basis of whether P-gp protein or its gene is
detected and whether the assay requires bulk tissue or if single cells can be analyzed.
Ideally, it is preferable to detect P-gp in individual cells. This type of assay allows for the
determination of tissue heterogeneity and the ability to discriminate between normal and
malignant cells_2° If normal cells expressing P-gp are present in the tumor specimen, then
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the ability to distinguish normal from malignant cells is obviously also important. One of
the major problems in determining the role of P-gp in clinical drug resistance is the
diverse results obtained for a given tumor, even using the same assay such as
immunohistochemical detection. For example, published results of the incidence of P-gp
in breast cancer are quite variable. This may be due to the fact that criteria are frequently
different depending on the experience of the individual investigators. Therefore, it is not
surprising that there are discrepant results reported for this disease. General acceptance of
laboratory criteria would appear to be critical for addressing the question of prognostic
significance of P-gp in clinical tumors.i''
Despite the numerous potential problems of detecting P-gp in clinical specimens,
general agreement regarding the frequency and magnitude of expression of P-gp has been
established for certain malignancies. These malignancies can be categorized as having a
high, moderate, or low level of P-gp expression." Tumors categorized as having a high
level of P-gp at time of diagnosis are derived from tissues that normally express high
levels of P-gp, such as kidney, colon, liver, and adrenal gland. These tumors are
classified as being drug resistant from the time of diagnosis; however, mechanisms of
drug resistance in addition to P-gp may be in place and it is not possible to ascribe
clinical drug resistance to the presence of P-gp alone in these tumors.i'' Demonstrating a
relationship between P-gp expression and response to therapy will probably be more
feasible in tumors that acquire the MDR phenotype. Malignancies such as childhood
sarcomas, breast cancer, malignant lymphomas, multiple myeloma and acute leukemias
represent a class of tumors that are generally considered to be drug responsive, but have a
significant percentage of patients who relapse presumably due to the development of drug
resistance. For example, P-gp positivity was revealed in 30-50% of acute myeloid
leukemia cases, and this protein was more often found after courses of chemotherapy. In
multiple myeloma, approximately 6% of patients are found to be P-gp positive and after
therapy up to 85% of patients resistant to treatment become P-gp expressing. On the other
hand, some studies of chronic myeloid leukemia show that P-gp expressing cells
disappear under therapy using drugs that are P-gp substrates, instead of multiplying under
these conditions. Although caution is needed for the comparison of the results of various
studies, it is possible to state that P-gp plays a role in the reaction of patients to therapy
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and that it can serve as a sign of poor prognosis. However, P-gp does not always
determine by itself the resistance to treatment. 10Analyzing for P-gp before and after
chemotherapy in patients who acquire the multidrug resistance phenotype will probably
be more informative in determining the prognostic significance of P-gp than studying
patients who have malignancies that are considered to be drug resistant de novo_2°
In general, controlled studies are essential to understanding pharmacokinetic and
pharmacodynamic drug interactions. A large number of trials investigating
chemosensitizers have had only a few patients whose tumors responded to a
chemotherapeutic regimen which included the addition of a chemosensitizer. This lack of
response in the initial trials has prompted some investigators to believe that P-gp
mediated multi drug resistance is not an important factor in the therapeutic outcome in
human malignancies.Y Reasons for this lack of response include large interpatient
variability in the disposition of anticancer drugs such as age, lean body mass, renal and
hepatic function, plasma protein binding, concomitant medications and variations in
CYP450 function. Interpatient variability of anticancer drug disposition in the order of
50-100% is commonly observed and would obscure the detection of effects attributable to
a chemosensitizer.l" The following bullet points (summarized from Reference 42) also
describe the difficulty of conducting clinical trials to assess the effectiveness of adding
chemosensitizers to chemotherapy regimens.
• The number of responders in phase I and II trials are expected to be low since
most patients who are entered in these trials have relapsed or refractory disease.
• The optimal methods for detecting P-gp have not been standardized. Many trials
did not attempt to categorize the level of expression ofP-gp in patients' tumors.
• Achieving therapeutic levels of reversal agents in the micromolar range has been
problematic due to toxicities and often not determined in many of the trials.
• The quantity of chemosensitizer required for complete P-gp inhibition has been
underestimated based upon in vitro results.
• The pharmacokinetics and biodistribution of these compounds have not been
totally defined for their use in cancer therapy and side effects have been the
limiting factor in administration of the reversal agent in a number of protocols.
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• It is not clear if chemosensitizers which inhibit P-gp would be most effective in
modifying intrinsic resistance or preventing acquired resistance.
• Clinical resistance to chemotherapeutic agents is most certainly multifactorial.
Agents which inhibit P-gp may ultimately be part of an armamentarium to
circumvent or prevent the development of multiple mechanisms of drug resistance
in human malignancy.
• The highest numbers of responses to chemosensitizers have been demonstrated in
hematopoietic malignancies including leukemia, lymphoma, myeloma and
Hodgkin's disease. Whether this relates to exposure of the malignant cells to
therapeutic agents or basic biological differences is not clear.
• Due to pharmacokinetic interactions, the increased delivery of chemotherapeutic
agents to the tumor has the potential to confound the interpretation of P-gp
reversal trials. Such trials need to be designed to demonstrate that a molecular
interaction between P-gp and the reversal agent is responsible for improved
efficacy and not simply an increase in the serum level of the cytotoxic agent.
The majority of agents used clinically for attempts at modulation of multi drug
resistance by P-gp are protein bound following administration. The degree of binding
varies between 70-90% for agents such as verapamil, quinidine, cycJosporine and
amiodarone, all of which have undergone clinical testing. It has been suggested that
protein binding of MDR modulators in the systemic circulation can reduce drug
availability of the pharmacologically active free drug fraction at the tumor site. However,
this view is unnecessarily simplistic and does not justify the generally accepted
physiologic concept of the extent of distribution of a compound within tissues, including
a tumor. In attempting to extrapolate in vitro to in vivo expectations, many investigators
tend to lose sight of the fact that the plasma comprises a relatively small fraction of the
total volume available for drug distribution, and that protein-drug complexes of rather
extraordinary stability must be formed to substantially reduce the amount of drug that
exists in the body in the active, diffusible, unbound form. Ideally, concentrations at the
tumor cell should be measured directly, and such studies are now underway." Table 1.5
(adapted from Reference 43) lists optimal in vitro concentrations ofMDR modulators and
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their achievable in vivo concentrations. These results suggest that the maximum clinical
achievable plasma concentrations are very close to the optimal concentrations needed to
overcome multidrug resistance. Due to toxicities, this may not be possible to achieve in
vivo, however. Far outweighing a potential importance of protein binding is the ability of
modulators to both (1) reach their target in solid tumors at sufficiently high
concentrations; and (2) achieve inhibition of P-gp activity. This is compromised by the
high cell density in patients' tumors (composed of 109 cells) that are rarely used in tissue
cultures (composed of 105 cells).
Table 1.5 Correlation between in vitro and in vivo plasma chemosensitizer
concentrations
Modulator Optimal in vitro Clinically achievable plasma
concentration concentration
Verapamil 6 ~lM 1 - 2 ~lM
Quinidine 6~M 6~M
Amiodarone 2~M 2 - 6 u.M
Cyclosporine 1 - 5 ug/ml. 1 - 6 ug/ml.
Tamoxifen 2 - 6 ~M 6 u.M
Toremifene 2.5 - 5 ~lM 3 - 6 ~lM
The time line needed for a cancer cell to be exposed to a multidrug resistance
modulator in order for it to be effective has not been completely established in vivo. One
study suggests that the duration of exposure of tumor cells to the modulating agent prior
to exposure to the cytotoxic agent does bear on the extent to which resistance is reversed.
It seems likely that a minimum of 24 hours of exposure is appropriate, and if the
modulating agent is being given orally, about 2-3 days of treatment may be necessary to
allow a plateau concentration to be achieved; this would depend on the half-life of the
modulating agent, patient specific factors such as protein binding, liver function, renal
elimination, and any other pharmacokinetic interactions"
Design of future clinical trials using chemosensitizers will depend on the desired
end point or objective. Phase I studies should include pharmacokinetic analysis of both
the modulator and the anticancer drug involved in order to exclude a potential
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In summary, the identification of P-gp as a mechanism of resistance to multiple
chemotherapeutic drugs creates a whole new approach to the treatment of cancer patients.
Diagnostic tests are now available to determine the prevalence of this drug resistance
gene in tumors. The results to date demonstrate that the expression of P-gp correlates
with the emergence of drug resistance in certain hematopoietic malignancies and
childhood tumors. Given these findings, it is reasonable to try to prevent or circumvent
this form of drug resistance in the clinic. The use of chemosensitizing agents to inhibit
the function of P-gp has received a great deal of attention in both the laboratory and the
clinic. Several studies using first generation chemosensitizing agents, such as verapamil
and cyclosporine, have reported encouraging results in reversing MDR_2o It is possible
that the discovery of new compounds that target P-gp or novel formulations that contain
existing compounds may dramatically improve the response to chemosensitizers that has
been observed in clinical trials to date.
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SIGNIFICANCE, HYPOTHESIS AND OBJECTIVES
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2.1 Significance
The deleterious role of multi drug resistance in cancer is by no means a debatable
one. The first chapter reviewed multiple reasons that a patient or patient population might
relapse or fail to respond to initial therapy. In vitro studies have shown that the
overexpression of an efflux protein, p-glycoprotein, is able to prevent the intracellular
accumulation of a wide variety of drugs that differ in their chemical structure and
mechanism of action. In vivo studies have shown that P-gp is present in many types of
tumors prior to chemotherapy and can be present in even higher amounts post
chemotherapy. Therefore, the presence of P-gp in tumor cells may have a prognostic
implication for a patient's response to therapy. Because of the importance of the role of
P-gp as one cause of multidrug resistance, multiple compounds have been reviewed in
their ability to inhibit P-gp. Some of these compounds, such as verapamil or
cyclosporine, have been very successful in inhibiting P-gp in vitro, but their use in vivo is
limited by their toxic effects. In other words, it is impossible clinically to achieve serum
concentrations equal to the in vitro concentrations needed to inhibit P-gp without causing
unfavorable side effects for the patient. Novel compounds have been developed to avoid
these toxicities, increase the potency of the inhibitor, and limit pharmacokinetic
interactions with chemotherapeutic agents but nevertheless, their efficacy in clinical trials
has not been consistent. Many surfactants have also shown benefit in reversing multidrug
resistance due to the overexpression of P-glycoprotein. In vitro studies have shown that
surfactants may have a unique mechanism of inhibiting P-gp: mainly by modulating the
f1uidity of the lipid membrane and inhibiting P-gp ATPase activity. A few in vivo studies
looking at formulations of lipids and chemotherapies in combination have also shown
success in increasing the accumulation of the chemotherapeutic agent intracellularly.
There have been virtually no studies, however, that have studied the benefit of adding
two different P-gp modulators together to reverse MDR (i.e., a first generation
chemosensitizer and a surfactant). A successful emulsion formulation consisting of the
first generation chemosensitizer, cyclosporine, and the surfactant Pluronic® 85 have been
developed previously by fellow researchers'f in our laboratory. This work is to determine
the effect of this formulation on reversing P-gp mediated multi drug resistance of cancer
cells in vitro.
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2.2 Hypothesis
We hypothesize that optimal doses of a P-gp inhibitor combined with optimal
doses of surfactant, also a P-gp inhibitor, formulated in a novel sub-micron emulsion
would lead to greater intracellular accumulation of a P-gp substrate compared to either
agent alone.
The novelty of this hypothesis is based on the following:
I. Cyclosporine and Pluronic® P-85 have different mechanisms of action in
inhibiting P-gp activity, which could possibly lead to a synergistic effect.
II. This formulation leads to the potential to use water soluble and water
insoluble drugs in one delivery vehicle.
III. This novel formulation would allow exposure of the cancer cell to
chemosensitizers and potential chemotherapeutic agents at the same time.
IV. It is more cost effective to develop a novel formulation of known
compounds than to develop a new compound with unknown side effects
and drug interactions.
2.3 Specific Objectives
I. Study the accumulation of Rhodamine 123 (RI23), a fluorescent dye
which acts as a P-gp substrate and serves as a measure of P-gp
functionality in the multi drug resistance cancer cell line MES-SA-Dx5.
II. Find the optimal cyclosporine concentration which inhibits P-gp.
II. Find the optimal Pluronic® P-85 concentration which inhibits P-gp. P85 is
a surfactant that reverses MDR and is used in formulating emulsions.
III. Develop O/W emulsions loaded with the P-gp substrate R123 and MDR
modulator cyclosporine.
IV. Develop a high performance liquid chromatography (HPLC) method to
detect cyclosporine in emulsion formulations.
V. Compare P-gp inhibition of cyclosporine in emulsions versus in solution.
VI. Perform western blots to study changes in the quantity of P-gp in aging
cells
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2.4 Approach
Rhodamine 123 was chosen as a P-gp substrate because it is also a fluorescent dye
and the extent of its intracellular accumulation could easily be determined by
fluorescence spectroscopy. Chemotherapeutic agents were not included as a component
of our formulations due to the cytotoxic risks of exposure and also because the presence
of a chemotherapeutic agent was not relevant to our focus on the P-gp functional studies.
The intent of this study was to determine the extent of reversal of P-gp inhibition by
measuring the intracellular accumulation of one of its substrates rather than the extent of
cell kill by a chemotherapeutic agent. The cancer cell line MES-SA-Dx5 was chosen
because it overexpresses P-gp and is readily grown in cell culture. Cyclosporine and
Pluronic@ P-85 were selected to be P-gp inhibitors because they had been formulated into
a stable emulsion formulation by fellow researches in our laboratory. 52 The purpose of
this study was to determine what would be the optimal concentrations of cyclosporine
and Pluronic® P-85 to use in emulsion formulations that would provide the greatest P-gp
inhibition and would still allow for a successful emulsion formulation.
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3.1 Background and purpose
As discussed previously, targeting P-gp as a mechanism of reversal of multidrug
resistance may improve the response to chemotherapy clinically. A multitude of P-gp
inhibitors have been studied both in vitro and in vivo. Cyclosporine is a first generation
chemosensitizer that is one of the most potent P-gp inhibitors in vitro. Unfortunately, the
use of cyclosporine in vivo has been limited by its toxic side effects. Pluronic® P-85 is a
surfactant that is also one of the most potent modulators of P-gp in vitro. The purposes of
these experiments are outlined in the following bullet points.
• To determine the optimal concentration of cyclosporine that would inhibit P-
glycoprotein.
• To determine the optimal concentration of Pluronic@ P-85 that would inhibit P-
glycoprotein.
• To determine the concentration of Pluronic'" P-85 that is the critical micelle
concentration (CMC). The CMC is the concentration at which the surfactant
aggregates into micelles and is no longer as available to interact with cells. The
concentrations of Pluronic@ P-8S below the CMC are the optimal concentrations
to formulate an emulsion because at these concentrations the surfactant exists in
formulation as unimers and has the ability to intercalate into lipid membranes and
interact with the cell.
3.2 Materials
The P-gp expressing multi drug resistant uterine cancer cell line MES-SA-Dx5
(CRL-1977) and McCoy's SA medium with L-glutamine were obtained from American
Type Culture Collection (ATCC®, Manassas, VA). Sterile fetal bovine serum (triple
Oi l um filtered) was obtained from Atlanta Biologicals'" (Atlanta, GA). Media was
prepared by mixing McCoy's SA medium with fetal bovine serum (FBS) to contain 10%
v/v FBS. Rhodamine 123 was obtained from Sigma Aldrich,@ (St. Louis, MO). Pluronic@
P-8S was obtained from BASF Corporation" (Mount Olive, NJ). DMSO
(dimethylsulfoxide) was obtained from Fisher Scientific Company" (Fair Lawn, NJ).
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3.3 Cell culture methods
MES-SA-Dx5 cells were routinely grown as monolayer cultures in 75 cm2
polystyrene cell culture flasks. The cultures were maintained at 37° C in an atmosphere
of 5% C02. McCoy's 5A medium was replaced every third or fourth day as needed until
the cells were ready to be harvested (at 80-90% conf1uency). A portion of the cells were
reseeded in the 75 cm2 f1asks and allowed to reach 80-90% conf1uency of the flask. The
second portion of cells were seeded in 96-well plates at 40,000 cells per well in McCoy's
5A medium and were allowed 24 hours to reach 80-90% conf1uency of the wells.
McCoy's 5A medium was removed by aspiration upon reaching conf1uency and the wells
were refilled with the appropriate control and experimental solutions as explained below.
The third and final portion of cells was stored in liquid nitrogen for future use if needed.
Cells were grown and stored for about 24 passages, each passage defined as each time
cells were harvested and allowed to reach 80-90% conf1uency of the flask. After about 24
passages the cells were considered to no longer be healthy and were discarded.
3.4 MTT assay of cell viability methods
The MTT (3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
is a widely used colorimetric assay that determines cell viability. The assay is based on
the reduction of the solute to form purple water-insoluble crystals by mitochondrial
succinate dehydrogenase, an enzyme present only in living cells. The extent of the purple
color directly correlates to cell viability. The more purple in color the solution in the well,
the more living cells are present. Cells were seeded in a 96-well plate at 40,000 cells per
well and allowed 24 hours to reach confluency. The cells were grown only in the inner 60
wells and the peripheral wells were filled with media. This was done to minimize the
"edge effect" where the media from the outer wells tends to evaporate faster than the
inner wells. Varying concentrations of dimethylsulfoxide (DMSO) (blank, 2.5, 5, 10, 15,
20, 25%) were applied in each row of the plate and allowed to incubate for 30 minutes in
the presence of the equal amounts of MTT solution. The purpose of this experiment was
to determine the lowest concentration of cytotoxic DMSO that would solubilize
cyclosporine while still allowing for the highest possible cell viability.
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3.5 Rhodamine 123 uptake studies for optimal cyclosporine concentration
Following the determination of the concentration of DMSO that would solubilize
cyclosporine with minimal cell death (through the MTT assay), solutions of cyclosporine
(1, S, 10, IS, 20, 2S ~lM)were prepared in 2.S% DMSO and McCoy's SA medium. The
various concentrations of cyclosporine solutions were applied in each row of the prepared
96-well plate in the presence of a constant concentration of 3 ~M R123 and were
incubated for 90 minutes at 37° C in an atmosphere of S% CO2. Each well was washed
three times with room temperature McCoy's SA medium after the incubation period. The
purpose of washing was to remove any residual molecules ofR123 present on the surface
of the cell that would confound the fluorescence spectroscopy measurement. All solution
was then removed from the wells and the accumulation of R 123 within the cells was
determined by f1uorescence spectroscopy. The fluorescence was read in a GenTek
spectrophotometer. The protocol for fluorescence spectroscopy was previously developed
by fellow researchers in the laboratory also using R123 in experiments. The effect of
each concentration of cyclosporine was studied in triplicate experiments.
A standard curve for R123 was developed to determine the concentration ofR123
accumulating inside cells prior to the fluorescence readings being measured for the
experimental plates. Increasing concentrations of R123 from O.S ug/ml. to SOO ug/ml,
were dissolved in nanopure water and added to rows of a 96-well plate. The fluorescence
of this plate was read and formulated into a standard curve based on linear regression as
shown in Figure 3.l. Using the equation generated from this standard curve, the R123
accumulation inside the cells after cyclosporine experiments was able to be determined.
This standard curve was developed for each experiment to account for day to day
variations in the environment and personal errors in measurement techniques.
3.6 Pierce BCA protein assay for normalization of data in cell viability
experiments
After the accumulation of R123 was determined by fluorescence spectroscopy,
the total amount of protein in each well was accounted for by the Pierce BCA protein
assay. This was done to account for the true number of cells present in each individual
well following the various stresses of experimentation, as this serves as the true
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representation of the fluorescence uptake by live cells. During experimentation, the cells
might detach from the 96-well plate because of 1) the physical force of washing each
well in triplicate with media as described in the section above; (2) the administration of
cytotoxic DMSO; and (3) the limited amount of media during the application of
cyclosporine solutions may starve cells, ultimately leading to necrosis and cell
detachment. Although we may assume a certain amount of cell death with the use of
DMSO, based on our previous experiments, we cannot assume the total amount of cell
loss due to daily variations in environmental conditions. The Pierce BCA protein assay
accounts for this unpredictability by quantifying the amount of protein in each well,
which correlates to the number of cells present. The R123 accumulation results for each
well were then divided by this number in order to normalize the data. Without this
essential step, the results from wells that had an unpredictable loss of cells during the
experimental procedure would be underestimated and the results from wells in which the
cells remained intact would be overestimated.
To determine the quantity of protein in each well, the 96-well plate was read in
the fluorescence spectrometer and 100 u.Lof Pierce BCA protein solution were applied to
each well and allowed to incubate for 30 minutes at 37° C in an atmosphere of 5% C02.
Meanwhile, albumin solutions at increasing concentrations from 25 ug/rnl. to 2000
ug/ml. were applied to a separate 96-well plate at 25 uL per well. The same Pierce BCA
solution that was applied to the cells (100 ul, of solution) was also applied to the albumin
plate. The absorbance of this plate were determined in a spectrometer and used to
generate a standard curve as shown in Figure 3.2. From this standard curve, the amount
of protein present in each well of the experimental 96-well plate was determined. This
standard curve was developed for each experiment to account for differences in cell loss
due to experimental procedures. Following incubation in the Pierce BCA solution, the 96-
well plate was read at the same wavelength as the albumin standard curve. Based on the
absorbance values read from this plate, the amount of protein in each well was able to be
determined with the equation generated from the standard curve (Refer to Figure 3.2).
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p3.7 Rhodamine 123 uptake studies for optimal Pluronic® P-85
concentration
Unlike the cyclosporine solution experiments, Pluronic® P-8S is readily soluble in
McCoy's SA medium and the solvent DMSO was not needed to solubilize P-8S.
Solutions of P8S (100 ug/rnl. to 1000 ug/ml.) were prepared in McCoy's SA medium.
Cells were seeded at 40,000 cells per well in 96-well plates and allowed 24 hours to reach
80-90% conf1uency. The various concentrations of P8S were applied in each row of the
plate in the presence of a constant concentration of 3 u.MR123 and were incubated for 90
minutes at 37° C in an atmosphere of S% CO2 Each well was washed three times with
room temperature McCoy's SA medium after the incubation period. The purpose of
washing was to remove any residual molecules of R123 present on the surface of the cell
that would confound the fluorescence spectroscopy data. After washing, all solution was
removed from the wells and accumulation of R123 within the cells was determined by
fluorescence spectroscopy. Following all experiments with P8S, R123 standard curves
were developed to determine the amount of accumulation of R123 within the cells and
the protein assay was applied to quantify the amount of cell loss.
3.8 Results and Discussion
Cyclosporine was found to be poorly soluble in McCoy's SA medium because it
IS a highly hydrophobic molecule and precipitates out in the hydrophilic McCoy's
medium. Therefore, the co-solvent dimethylsulfoxide (DMSO) was needed to solubilize
it. DMSO, however, is highly toxic to cell culture. The MTT assay was conducted to
determine the cell viability of cells exposed to cyclosporine and DMSO. It was
determined that 2.S% DMSO can solubilize cyclosporine. As shown in Figure 3.3, this
percentage of DMSO leads to about 8S% cell viability. This concentration of DMSO was
applied to all experiments using cyclosporine in solution.
Figure 3.4 shows the amount of R123 accumulation 111 the presence of the
cyclosporine solutions normalized with the Pierce BCA protein assay. It was found that
the greatest amount of R 123 accumulation occurred in the presence of 15 ~lM
cyclosporine. There was a dose response relationship between R123 accumulation and
cyclosporine concentration up to IS ~M of cyclosporine beyond which R 123
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Figure 3.4 Cyclosporine-Rhodamine 123 uptake studies in MES-SA-Dx5 cells
[data normalized using the Pierce BCA protein assay}
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3.9 Conclusion
Out of the cyclosporine concentration from 1 uM to 25 ~M, 15 ~M led to the
greatest intracellular R123 accumulation. Out of the Pluronic® P-85 concentration from
100 ug/rnl, to 1000 ug/ml., 450 ug/ml. led to the greatest intracellular R123
accumulation. These optimal doses of cyclosporine and Pluronic® P-85 were used to
prepare O/W sub-micron emulsion for further studies.
49
CHAPTER IV
PREP ARA nON OF SUBMICRON EMULSIONS AND ANALYSIS OF
CYCLOSPORINE CONTENT BY HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY
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4.1 Background and purpose
An emulsion formulation consists of an oil phase, a water phase, and a surfactant
and/or co-surfactant. The benefit of emulsions as drug delivery systems is that because of
the presence of an oil phase and a water phase, they are able to incorporate both lipid
soluble and water soluble drugs in one formulation. Due to its amphiphilic properties, the
purpose of the surfactant is to decrease the tension between the oil phase and the water
phase by forming droplets which allow the two phases to be equally dispersed and
prevent the two layers from separating out (i.e. cracking of the emulsion). When an oil
phase, a water phase and a surfactant are introduced into one delivery vehicle, the
ingredients are able to self-emulsify without any energy added into the system. However,
in this type of emulsion, the droplet is larger in size (micrometer range) and requires large
amounts of surfactant in order to self-emulsify. Adding energy into the formulation
reduces the particle size significantly, reduces the amount of surfactant needed, and
extends the shelf life of the formulation. Previous work in the laboratory has shown that
using high energy equipment, such as a microfluidizer, can produce a significantly
smaller droplet size (nanometer range) with a smaller amount of surfactant. These
emulsions, termed sub-micron emulsions, are effectively studied in tissue culture.
The purpose of these experiments were to formulate oil-in-water (O/W) sub-
micron emulsions, meaning that the external phase exposed to the environment is the
water phase and the oil phase is incorporated internally by the use of surfactant. There are
many factors that contribute to the formulation of a stable sub-micron emulsion including
type of surfactant used, order of mixing the components, temperature at which it is
stored, and others. The formulation of the sub-micron emulsions used in the following
experiments was previously characterized in the laboratory and is repeated in this
research project. Once the emulsions were prepared, particle size was monitored prior to
administering the emulsion in tissue culture. A method to quantify the amount of
cyclosporine in each emulsion was also developed and is outlined below.
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4. 2 Materials
The oil used was Labrafil® M 1944 CS (Gattefosse, France). Pluronic@P-85 was
obtained from BASF Corporation'" (Mount Olive, NJ). Double distilled filtered water
obtained from the Nanopure'" water system was used during the entire study. HPLC grade
acetonitrile was obtained from EMD Chemicals Inc® (Darmstadt, Germany).
4.3 Preparation of sub-micron emulsions
Oil-in-water submicron emulsions were prepared by high pressure
microfluidization. Based on previous research, Labrafil® M 1944 CS 10% w/w and
Pluronic® P-85 2.5% w/w were used to formulate the emulsions. Five different coarse
emulsions (50 mL each) containing varying concentrations of cyclosporine (1, 5, 10, 15,
20, 25 11M) were prepared by accurately weighing the components and stirring the
mixture using a magnetic stirrer for five minutes in glass beakers. Note that the
concentration of 15 u.M cyclosporine which was found in the previous chapter to be the
optimal concentration of cyclosporine is included in this range. The emulsions were
milky in appearance and were processed through the microf1uidizer at room temperature.
The inlet pressure was maintained at 18,000 psi and each batch was processed for twenty
discrete volume cycles.52 This number of volume cycles was previously determined to
decrease droplet diameter and increase long term stability of the submicron emulsion.
The prepared submicron emulsions were stored in borosilicate glass vials at room
temperature. After undergoing the microfluidization process, the submicron emulsions
appeared transparent due to droplet size reduction to the nanometer range. The droplet
size was confirmed by particle size analysis immediately after microfluidization and then
periodically thereafter, all values remaining between 200 to 500 nanometers.
4.4 High Performance Liquid Chromatography Method Development for
cyclosporine detection in emulsion formulations: results and
discussion
After the emulsions were prepared, a method was needed to quantify cyclosporine
in emulsions to ensure that the cyclosporine content remained intact after processing the
crude emulsion through the microfluidizer. High performance liquid chromatography
(HPLC) is a quantification method that uses hydophobicity to separate compounds in a
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mixture. The first step in HPLC development is to determine the ideal mobile phase. The
mobile phase is a mixture of different solvents combined in a ratio that will solubilize the
solution to be quantified and prevent it from precipitating within the column. As the
mobile phase runs through the column, the components of the sample are separated and
detected by an ultraviolet detector. The mobile phase typically consists of 50% organic
material. The percentage organic material within the mobile phase can then be increased
or decreased depending on the amount of time it takes for the sample to run through the
column. For example, if the sample is hydrophobic and is running too fast through the
column in order to be detected, the percentage organic phase may be decreased. An ideal
baseline is horizontal and does not absorb any of the ultraviolet light from the detector.
Figure 4.1 is an example of a bad baseline which absorbs the ultraviolet detection and
indicates an adjustment needed in the components of the mobile phase.
Figure 4.1 Screen shot of a bad baseline during HPlC method development
The horizontal axis of Figure 4.1 is the time of the run and the vertical aXIS
indicates the quantity of substance present in the sample. It was determined that a 90: 10
ratio of acetonitrile to degassed nanopure water is the ideal mobile phase to detect
cyclosporine.
The second step in HPLC method development is choosing a column. The column
consists of silica material to which different amounts of hydrocarbons are attached. For
example, a C 18 column would be considered more hydrophobic than a C8 column.
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Therefore, a hydrophobic compound would be attracted to the material in this column
more strongly and would take a longer time to run through the column than it would in a
C8 column. The length of the column also determines the amount of time a sample takes
to run through the column. To determine the best column to use, increasing
concentrations of cyclosporine were dissolved in DMSO and run through different
columns in the presence of 90: 10 acetonitrile. Figure 4.2 is an example of increasing
concentrations of cyclosporine solution run through a shorter C8 column (on left) and a
longer C8 column (on right). It is clear that the length of the column is one determinant of
how long a sample will take to run through a column. For this research, a C8 x 250
x SuM mm column was chosen.
Figure 4.2 Screen shot of influence of column length on time to sample peak
The third step of HPLC method development is to optimize the drug peak. An
ideal drug peak is sharp and clearly distinct from solvent peaks. Figure 4.3 is an example
of a drug peak that is not completely separated from the solvent peak. In order to separate
sample peaks from solvent peaks, the organic component of the mobile phase can be
adjusted, a different type or length of column may be used, or the solvent itself may be
changed.
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Figure 4.3 Screen shot of sample peak too close to solvent peak
The second peak in Figure 4.3 was determined to be the drug peak because when a higher
concentration of cyclosporine (top line) was run under the same conditions, a higher peak
was found in the same location. This is further illustrated in Figure 4.4.
Figure 4.4 Screen shot of discrimination of sample peak from solvent peak
After the most appropriate column and mobile phase are chosen and the drug peak
is optimized, the next step in method development is to develop a standard curve for the
sample. Nine two-fold serial dilutions of 500 ug/ml. of cyclosporine were dissolved in
DMSO and run through a mobile phase of 90: 10 acetonitrile. The HPLC software is able
to calculate an area under the curve (AUC) for each peak which correlates to the
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concentration of cyclosporine in the sample. The purpose of the standard curve is to be
able to calculate the amount cyclosporine in emulsions when they are run through the
HPLC system. The standard curve for cyclosporine in DMSO generated a con-elation
coefficient (R2) of 0.9995 as shown in Figure 4.5. A correlation coefficient is a measure
of the strength between two variables. A value close to 1.0 is indicative of a very good
correlation.
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Once it was determined that it was possible to detect cyclosporine in the column
and the mobile phase was chosen, the next step in HPLC method development was to run
the cyclosporine emulsions through the HPLC column. Unfortunately, it was found that it
takes a long time for the oil component of the emulsion to run through the column.
Cyclosporine does not separate easily from the oil component of the emulsion and is
therefore difficult to accurately quantify. The oil is also destructive to the material that
makes up the column.
o 100 200 500300 400
Cyclosporine Concentration (ug/mL)
HPLC standard curve of cyclosporine solubilized in dimethylsulfoxide
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Extractions were prepared in order to avoid having to inject oil through the
column. An extraction is a physical way to separate out the components of a mixture
depending on their densities. Increasing concentrations of cyclosporine were dissolved in
oil and crude emulsions were prepared in a ratio of three parts mobile phase to one part
oil and were left overnight in a separating funnel. Since the oil was denser than the
mobile phase, a portion of the mobile phase was able to be removed from the top of the
extraction. A series of dilutions were made from this top portion and run through HPLC.
The purpose of this experiment was two-fold: (1) to determine how much cyclosporine
partitions between the oil and the mobile phase; and (2) to determine if the extraction
method can be used to quantify cyclosporine but minimize the amount of oil that is
injected into the HPLC column. It was determined that although it appeared that the oil
had completely separated from the mobile phase, microscopic particles of oil were still
dissolved in the mobile phase. Figure 4.6 demonstrates how the oil gradually bleeds
through the column, with each peak containing a small quantity of cyclosporine.
Figure 4.6 Screen shot of result of oil running through HPLC column
Although it was surprising that a small quantity of oil was contained in the mobile phase
of the extraction, cyclosporine was still more easily quantified in the extraction than by
directly injecting the cyclosporine sub-micron emulsions through the HPLC column. To
determine how effective this extraction method of quantification is, the AUC for each
peak in the screen shot was added together and a standard curve was developed. The
standard curve, shown in Figure 4.7, generated a correlation coefficient (R2) of 0.9949.
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Figure 4.7 HPLC standard curve of cyclosporine extractions
Although the extraction method of quantification developed a successful standard
curve, it was very time consuming to prepare the extraction, run the HPLC until no more
oil is left in the column, and then add up the total AUC of all the peaks generated for one
sample. Furthermore, it is not known exactly how much CyA is diffusing from the oil
into the mobile phase. To further improve on the extraction method of quantification, the
experiment was repeated in two parts. In the first part (depicted as Part A in Figure 4.8),
extractions were made similar to as before. 1250 ug/ml. cyclosporine was solubilized in
oil and 90: 10 acetonitrile was added to the mobile phase in the ratio of three paris mobile
phase to one part oil. The crude emulsion was allowed 24 hours for the components to
separate. A portion of the mobile phase was removed and was separated out in a series of
five two-fold dilutions. In the second part (depicted as part B in Figure 4.8), 1250 ug/rnl.
6000
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of cyclosporine was solubilized in oil and five two-fold dilutions of this solution were
prepared. To each dilution, 90: I0 acetonitrile was added in the ratio of three parts mobile
phase to one part oil. Once again, these crude emulsions were allowed 24 hours to
separate. In theory, the amount of cyclosporine detected from Part A of this experiment
should be equal to the amount of cyclosporine detected in Part B of this experiment.
Figure 4.8 further illustrates the experimental set up.
Two-part Extraction Experiment
1 CyeA in oil:
3 Mobile phase
Same
concentration
CyeA in oil
~
Supernate
Supernates
Figure 4.8 Protocol for two-part extraction experiment. (MP: mobile phase)
The results showed that the CyA detected in Part B was two-fold higher than the
amount of CyA detected in Part A. Any oil still dissolved in the mobile phase of the
samples absorbed UV light from the detector confounding the results. One explanation
could be that every sample in Part B was exposed to oil whereas in Part A only the first
sample was exposed to oil and all the other samples were simply dilutions of that first
sample. Table 4.1 is a chart of the exact AUC values and the ratio of CyA measured to
CyA detected. These results suggest that oil is too much of a confounding factor for the
extraction method of quantification to be successful.
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HPlC Standard Curves for Two-Part Extraction
Experiment
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Figure 4.9 Comparison of HPLC standard curves generated from different
extraction methods of cyclosporine
1250 15346005 1049 0.83 1250 15061555 1028 0.82
625 9493329 621 0.99 625 13274861 898 1.4
312.5 3704465 197 0.63 312.5 11582111 774 2.4
156.25 2406861 102 0.65 156.25 9685524 635 4.6
78.125 1762868 55 0.71 78.125 8581026 554 7.1
Table 4.1 Data tables for extraction methods of cyclosporine. The last column of
each table is the ratio of the cyc1osporine detected (third column) to cyc1osporine
measured (first column).
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Extractions were then prepared from the sub-micron emulsions. It is possible that
sub-micron emulsions would behave differently than the crude emulsions that had been
prepared in the previous extraction experiments. In this next extraction experiment, 90:10
acetonitrile was added for each sub-micron emulsion that was prepared in a ratio of three
parts mobile phase to one part emulsion. They were allowed to sit for 24 hours for the
components to separate. The supernate of each of these samples was run through HPLC
and the amount of CyA was detected. Unfortunately, the results of this experiment as
seen in Figure 4.10 were not significant and no conclusion can be drawn from the data
obtained. These results can be explained by the fact that (1) the emulsion did not
completely separate out in the time allotted; or (2) the other components of the emulsion
(i.e. Pluronic® P-85) are having a confounding effect on the detection of CyA
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Figure 4.10 HPLC standard curve of extractions of cyclosporine emulsions
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The results of this experiment led to another question. Would the Pluronic® P-85
component of the emulsion have any confounding effect on the detection of cyc1osporine
like the oil had? To answer this question, another set of standard curves was developed.
Concentrations of cyclosporine from 10 ug/ml. to 140 ug/ml. were solubilized in
propylene glycol, a known solvent for cyclosporine used in HPLC. The identical set of
cyclosporine concentrations were solubilized in Pluronic® P-85. The two sets of standard
curves were then compared. If the amount of cyc1osporine detected in the Pluronic® P-85
solvent was significantly higher than the amount of cyclosporine detected in the
propylene glycol solvent, this would signify that Pluronic® P-85 would be absorbing
ultraviolet radiation from the detector and confounding the true amount of cyclosporine
present in the sample. However, the standard curve for the amount of cyclosporine in
propylene glycol nearly overlapped that of Pluronic® P-85, suggesting that Pluronic® P-
85 does not have either a positive or negative confounding effect.
Propylene Glycol vs. Pluronic 85 Standard Curves
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Figure 4.11 HPLC standard curves of cyclosporine solubilized in propylene glycol
versus cyclosporine solubilized in Pluronic® P-85
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It can be assumed that although extractions made from crude emulsions can be
used to develop a standard curve, extractions from sub-micron emulsions cannot,
Therefore, a totally new approach to quantifying cyclosporine in emulsion formulations
was needed. The theory for this approach is proposed in Figure 4.12. First, the
components of the sub-micron emulsions would be forced to separate through high speed
centrifugation. This would help separate the oil completely from the mobile phase. After
centrifugation, the supernatant would be removed and centrifuged a second time. This
would ensure that any oil left in the supernatant would be removed. The supernatant
would be removed again and left to evaporate in the solvent hood, leaving cyc1osporine.
Cyclosporine would then be resuspended in propylene glycol for HPLC detection. One
limitation to this approach is that it is still not known how much cyclosporine remains in
the oil phase after centrifugation and how much diffuses into the supernatant. If this
percentage could be figured out, then HPLC method development would be complete.
HPLe method development proposal
Figure 4.12 Proposal for HPLC method development of cycIosporine in emulsions
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4.5 Conclusion
It can be concluded that (1) the emulsions were stable based on particle size for
the period that they were studied; (2) oil interferes with the detection of cyclosporine that
can be detected in a sample by HPLC; (3) the extraction method of quantification does
not completely avoid the oil component of emulsions; (4) Pluronic® P-85 does not have a
confounding effect on the detection of cyclosporine; and (5) a potentially successful
approach to HPLC method development was proposed.
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CHAPTER V
RHODAMINE 123 UPTAKE STUDIES OF CYCLOSPORINE SUBMICRON
EMULSIONS VERSUS CYCLOSPORINE SOLUTIONS IN THE MULTIDRUG
RESISTANT CANCER CELL LINE MES-SA-Dx5
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5.1 Background and purpose
As discussed in Chapter I, the literature suggests that both cyclosporine and
Pluronic® P-85 are significant inhibitors of the efflux protein, p-glycoprotein (P-gp). This
efflux pump, when overexpressed in cancer cell lines, is able to prevent the intracellular
accumulation of a wide variety of drugs, despite differing chemical structures and
mechanisms of action. It has been suggested that the primary action of cyclosporine and
Pluronic® P-85 on reversing multi drug resistance is by modulating the activity of P-gp.
Although it is not completely known how these modulators affect P-gp, it is thought that
the two compounds have differing mechanisms of action. Cyclosporine is thought to have
a structure activity relationship with P-gp. Pluronic® P-85 is thought to inf1uence the
fluidity of the membrane and to inhibit the ATPase function of the protein. Since these
two modulators target different functions of P-gp, the combination of cyclosporine and
Pluronic® P-85 formulated in an emulsion may be more effective than cyclosporine alone
in solutions on enhancing the uptake of R123 in multi drug resistance cancer cells which
overexpress P-gp.
The purpose of these experiments IS to determine the amount of R123
accumulation in multi drug resistant cells that overexpress P-gp when exposed to
emulsions that contain both cyclosporine and Pluronic® P-85. This experiment was
conducted in the same manner as the cyclosporine solutions experiments were described
in Chapter III. The R123 accumulation results from these emulsion formulations were
then compared to the R123 accumulation seen from cyclosporine in solution.
5.2 Materials
The P-gp expressing multidrug resistant uterine cancer cell line MES-SA-Dx5
(CRL-1977) and McCoy's 5A medium with L-glutamine were obtained from American
Type Culture Collection (ATCC®, Manassas, VA). Sterile fetal bovine serum (triple
O.ll-lm filtered) was obtained from Atlanta Biologicals'" (Atlanta, GA). Media was
prepared by mixing McCoy's 5A medium with fetal bovine serum (FBS) to contain 10%
v/v FBS. Rhodamine 123 was obtained from Sigma Aldrich" (St. Louis, MO).
Pluronic® P-85 was obtained from BASF Corporation" (Mount Olive, NJ). DMSO
(dimethylsulfoxide) was obtained from Fisher Scientific Company" (Fair Lawn, NJ).
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5.3 Cell culture
MES-SA-Dx5 cells were routinely grown as monolayer cultures in 75 cm2
polystyrene cell culture flasks. The cultures were maintained at 3]0 C in an atmosphere
of 5% C02. McCoy's 5A medium was replaced every third or fourth day as needed until
the cells were ready to be harvested (at 80-90% confluency). A portion of the cells were
reseeded in the 75 cm2 flasks and allowed to reach 80-90% confluency of the flask. The
second portion of cells were seeded in 96-well plates at 40,000 cells per well in McCoy's
5A medium and were allowed 24 hours to reach 80-90% confluency of the wells.
McCoy's 5A medium was removed by aspiration upon reaching confluency and the wells
were refilled with the appropriate control and experimental solutions as explained below.
The third and final portion of cells was stored in liquid nitrogen for future use if needed.
Cells were grown and stored for about 21 to 24 passages, each passage defined as each
time cells were harvested and allowed to reach 80-90% confluency of the flask. After
about 21 to 24 passages, the cells were considered to be no longer healthy and were
discarded.
5.4 Rhodamine 123 uptake studies for emulsion formulations
The various concentrations of cyclosporine emulsions (prepared as described in
Chapter IV) were applied in each row of the 96-well plate in the presence of a constant
concentration of 3 11M R123 and were incubated for 90 minutes at 37° C in an
atmosphere of 5% CO2. Each well was washed three times with room temperature
McCoy's 5A medium after the incubation period. The purpose of washing was to remove
any residual molecules of R123 present on the surface of the cell that would confound the
fluorescence spectroscopy data. All solution was removed from the wells after washing
and accumulation ofR123 within the cells was determined by fluorescence spectroscopy,
A R 123 standard curve was developed as described in Chapter III and used to calculate
the quantity of RI23 that had accumulated within the cell. The Pierce BCA protein assay
was also performed to estimate protein content (to account for cell loss during the
experimental set up). It was observed that there was greater cell loss when the sub-micron
emulsions were applied to the cells as opposed to cyclosporine solutions. This can be
explained by the presence of oil and surfactant within the sub-micron emulsion
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formulations that increase the permeability of the cell membranes, causing them to be
more easily washed from the base of the 96-well plate. To note, each concentration of
sub-micron emulsion in tissue culture was repeated in triplicate. The cell culture
experiments of cyclosporine solutions described in Chapter III were also repeated at this
time to account for changes in environmental conditions and to confirm the results from
Chapter III. The amount of R123 accumulation by cyclosporine emulsions and
cyclosporine solutions was then compared by fluorescence spectroscopy.
5.5 Results and Discussion
The hypothesis of this experiment was that the R123 accumulation in cells
exposed to cyclosporine emulsions would be higher than the R123 accumulation in cells
exposed to cyclosporine solutions. The idea was that both cyclosporine and Pluronic®P-
85 would contribute to the inhibition of P-gp in a synergistic fashion. Figure 5.1 shows
that the opposite results were obtained. The R123 accumulation in cells exposed to
cyclosporine solution was higher than that in cells exposed to cyclosporine emulsion.
Recall that all experimental data was normalized based on total protein content estimated
by the Pierce BCA protein assay, so this difference is not due to a greater cell loss during
experimental procedures for the cells exposed to cyclosporine emulsions. One possible
explanation of these results is that cyclosporine and Pluronic'" P-85 may have a mutually
antagonistic effect on the function of P-gp. For example, if Pluronic® P-85 depletes the
amount of ATP within the cell, then cyclosporine would have no added benefit. The level
of R123 accumulation seen in Figure 5.1 from cyclosporine emulsions may actually be
due to the effect of Pluronic® P-85 alone, or vice versa. It is not entirely known which
MDR modulator has a greater effect on P-gp or which one works more quickly. Another
possible explanation for these results is the particulate nature of the droplets from the
submicron emulsions. In theory, the sub-micron emulsion should contain small particles
of cyclosporine solubilized in oil. These particles of oil should be surrounded by the
hydrophobic segments of P85 and the hydrophilic segments should face the outside of the
particle, where they can interact with water. It is possible that when the emulsion
particles interact with the cell, the intactparticles undergo endocytosis and cyclosporine
is released into the cytosol. Cyclosporine might not have as great an effect on P-gp in the
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cytosol as it does when in contact with the lipid membrane. Alternatively, if the intact
emulsion particles all undergo endocytosis, it is possible that neither cyclosporine nor
Pluronic® P-85 gets enough opportunity to interact with P-gp in the lipid bilayer. One
final possibility is that R123 is also somehow incorporated into the emulsion particle and
while it may in fact be accumulating inside the cell to a greater degree, the other
components of the emulsion are preventing it from being detected properly by
fluorescence spectrophotometry.
After the results of this experiment were noted, it was also found that the amount
of R 123 accumulation in cells exposed to cyclosporine solutions was still less than the
amount of R123 accumulation seen when this experiment was completed previously, as
described in Chapter III. In this current chapter, the R123 uptake studies of cyclosporine
in solutions were done on the sixth passage. However, the R123 uptake studies completed
in Chapter III were done on cells in their second passage. Because the older cells had less
accumulation of R123, it was thought that the cell line had up-regulated the expression of
P-gp due to the repeated exposure to R123. If more P-gp was expressed in older cells,
more cyclosporine would be needed to inhibit it. These results prompted the necessity to
quantify the amount of P-gp in cells of different passages and are explained in the next
chapter.
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5.6 Conclusion
The R 123 accumulation in cells exposed to cyclosporine submicron emulsions
was less than the R123 accumulation in cells exposed to cyclosporine solutions.
Furthermore, the amount of R123 accumulation in the cells exposed to cyclosporine was
less than what was shown in previous experiments. These results remain unexplained.
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CHAPTER VI
QUANTIFICATION OF P-GL YCOPROTEIN AMONG DIFFERENT CELL
PASSAGES IN THE MUL TIDRUG RESISTANT CELL LINE MES-SA-DX5
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6.1 Background and purpose
Multidrug resistance is indeed multifactorial, with cancer cells developing new
mechanisms of resistance constantly. It is important to keep this in mind even when
studying multidrug resistance in vitro. As described in the previous chapter, it is possible
that as the multidrug resistant cancer cell line continued to be exposed to P-gp substrates,
such as R123, it began to upregulate the expression of P-gp. Therefore, in later cells, it
was more difficult to get the same amount of R 123 accumulation intracellularly with the
same concentration of cyclosporine. This explanation, however, is only a hypothesis, so
the purpose of the experiments in this chapter is to quantify the amount of P-gp expressed
in earlier passages of cells and to compare to the amount expressed in later passages.
Western blotting was used to quantify the amount of P-gp present in cell samples.
Western blotting uses gel electrophoresis to separate denatured proteins based on size.
The proteins are then transferred to a membrane where they are detected by fluorescently
labeled antibodies specific to the protein.
6.2 Materials
The primary antibody used was Anti-Pgp rabbit pAb obtained from CaIBiochem®
(Lot # D00087835). The secondary antibody used was goat anti-rabbit IgO, HRP
conjugate obtained from Millipore" (Lot # OAMI749947). The protein marker used was
Color Plus Prestained Protein Marker Broad Range (7-175 kOa) obtained from BioLabs
(Lot # 29).
6.3 Western blotting
MES-SA-Dx5 cells were grown as monolayer cultures in 75 cm2 polystyrene cell
culture flasks. The cultures were maintained at 37° C in an atmosphere of 5% C02.
McCoy's 5A medium was replaced every third or fourth day as needed until the cells
were ready to be harvested (at 80-90% confluency). Once harvested, cells were
centrifuged at 3000 rpm for seven minutes. The supernatant was removed and the cells
were washed in 10 milliliters of cytobuster (Buffer A in Reference 51) for five minutes.
They were then sonicated at six watts for 10 seconds. The cells were then again
centrifuged at 1000g for 10 minutes at 4°C. The supernatant was removed and then the
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supernatant was agam centrifuged at 10,000g for 20 minutes at 4° C. The following
supernatant was discarded and the pellet fraction was washed in cytobuster and dissolved
in TNC buffer (10 mM Tris-acetate; 5 mM CaCb). The stacking gel (20% w/v SDS) was
then prepared and 10 uL of the sample was loaded in each well. The gel was allowed to
solidify and was run through gel electrophoresis at 300 rnA for 25 minutes. The gel was
then transferred to a membrane overnight at low voltage. Once the protein was
transferred onto the membrane, it was washed for thirty minutes with tris-buffered saline
and 5% w/v non-fat dried milk. It was then washed with phosphate buffered saline for
five minutes three times. The primary antibody was applied to the membrane for one
hour. The membrane was then washed with phosphate buffered saline for five minutes
three times. The secondary antibody was applied for two hours. The membrane was
washed once more with phosphate buffered saline and the protein was detected through a
ChemiMajor imager.
6.4 Results and discussion
Comparing Figure 6.1 (third passage) and Figure 6.2 (nineteenth passage), it is
apparent that there was greater P-gp expression in the earlier cell line. The average
optical density was 4.5xl07 for the third passage of the cell line and 1.7xl07 for the
nineteenth passage of the cell line. This implies that there might have been a
downregulation of P-gp expression as the cell lined aged. However, this is not consistent
with the previous results showing greater R123 efflux in older cells. In order for older
cells to have less accumulation, they would have to have a greater expression of P-gp. On
the other hand, it is possible that this cell line had developed other mechanisms of
effluxing R 123. It is also possible that the cell line obtained from ATCC was defective,
and could not keep the overexpression of P-gp beyond a certain number of passages.
Around this time, there was also a yeast infection developing in the incubator (detected at
a later time) so it is possible that these results were confounded by the presence of yeast
cells among the older cell line, which might not express P-gp at all. Because the cancer
cells may have been contaminated by yeast cells, lower levels of P-gp could have been
detected because the corresponding total protein content, as determined by Pierce BCA
protein assay, would have been high, negatively affecting the P-gp to total protein ratio.
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e experunental methods were also developed based off 0 t lose eSCIl
51 .. b btained with different
, so It IS possible that better or more accurate results can e 0
exp . ·f'C rimental methods to
enmental procedures. Future work should try di lerent expe
d t . f bt . . J a yeast infection
e ermme which is most effective and minimize the chance 0 0 ammg
or other forms of contamination in tissue culture.
Figure 6.1 Western blot of P-glycoprotein expressed in the third passage
of the cell line MES-SA-DxS
Figure 6.2 Western blot of P-glycoprotein expressed in the nineteenth passage
of the cell line MES-SA-DxS
6.5 Conclusion
The results of this experiment showed that there was greater expression of P-gp in
earlier cell passages than in later cell passages. However, these results may not be
accurate due to confounding factors as described and therefore they cannot be
conclusively explained. In general, in order for multiple experiments of Rhodamine 123
uptake studies to be truly comparable, they need to be conducted within the same cell
passage. This would eliminate any variations in P-gp expression that occur between
different passages.
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CHAPTER VII
CONCLUSIVE SUMMARY AND DISCUSSION OF FUTURE WORK
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7.1 Conclusive Summary
Th
' . f cyclosporine (15 f-lM)
IS work attempted to find the optimal concentratlOn 0 . . .
and f f • I' for the inhIbItiOn
o Pluronic® P-85 (450 ~g/mL) to formulate submicron emU Sionsfl .di t' n and the
or reversal of MDR. The emulsions were prepared through micro UI iza 10
cont t f . f . l'quid chromatography
en 0 cyclosporine was analyzed through hIgh per Olmance 1
(HPLC). Although several trials of HPLC method development were attempted, none
we 1 . experiments, likely
re tru y successful as the results failed to replicate over succeSSIve
du t h . 1 I mn chemistry. The
e 0 t e residual oil from the emulsion constantly changmg t le co u
em 1'" .' . , ulture but contrary
u sion formulations were studied for their effect on P-gp 111 ussue c ,
to' .' D nd to be more
Our expectanons, the solution formulatron of cyclosponne was ou
. . . . . ® P-85 did
effectrve 111 inhibiting the action of Pvgp. Furthermore, the surfactant Pluro
11lC
not enhance the Pvgp inhibition when added to cyclosporine in the emulsion formulation.
It is possible that the micellization of cyclosporine in the emulsions prevents its
interaction with Pvgp at the cell surface, leading to the reduced efficacy observed in our
experiments. Differences in protein expression between cell passages were explored
through Western blotting, but no definitive conclusion could be drawn based on the data
obtained.
7.2 Discussion of future work
Multidrug resistance in cancer continues to present a major challenge in
chemotherapy, especially when patients fail to respond to multiple chemotherapeutic
regimens. The overexpression of the efflux protein P-gp is a major cause of therapy
failure for some cancers. Therefore, therapy targeted to the inhibition of P-gp is
warranted and numerous clinical studies have been conducted in search for an etTective
chemosensitizer that can render current cancer treatments to be reliably effective across
the wide patient population. Nevertheless, no true benefit from anyone chemosensitizer
has been found to date. This research project took two of the most studied and potent
chemosensitizers, cyclosporine and Pluronic® P-85, and combined them in a novel
submicron emulsion formulation. This formulation could potentially have its niche in
chemotherapy regimens, but the tumors that will clearly benefit from P-gp inhibition will
first need to be characterized. It will also need to be determined if it is better to prevent
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the 0verexpression f
o P_gp by administering inhibitors before the multidrug resistant
phenoty pe occurs or if it is better to do so after the fact. In future in vitro work, the
proposed meth dsub . 0 of HPLC analysis will first need to be tested. If successful, the
mIcron emul .
b
sions can be studied further in tissue culture but all experiments should
e c . '
arried out witl .thr I un the same passage of cells. Determination of the expression of p-gp
ough Western bl ttio .mg should also be performed before and after each R123 uptake
study.
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